Latest News

A pressure vibration device can cut propofol injection pain in patients undergoing surgeries, matching low-dose ketamine without extra adverse events.

This century has seen a dramatic shortage of pharmacists, then a dramatic pullback, and now a selective shortage. Will artificial intelligence tip the scale? If so, in which direction(s) and which settings of care?

Pitolisant is now the first and only FDA-approved nonscheduled treatment for cataplexy in pediatric and adult patients with narcolepsy.

The FDA approves a once-monthly dosing schedule for amivantamab and hyaluronidase-lpuj to optimize administration and cut down infusion times.

The biosimilar is a cost-effective treatment for patients with conditions caused by cancer treatments.

Telehealth expands physical therapy and pharmacy support.

Explore the balance of ambition and self-care in cancer care, emphasizing curiosity, collaboration, and the importance of sustainable productivity.

Amivantamab with lazertinib emerges as a promising front-line therapy for EGFR-mutated metastatic NSCLC, enhancing overall survival and treatment tolerability.

With user expectations changing and the need to support patients throughout their entire treatment journey, growing technology-enabled communication allows pharmacists to build stronger relationships and go beyond prescription fill.

ALZ-801, an oral anti–amyloid oligomer therapy, shows cognitive, functional, and brain-volume benefits in the mild cognitive impairment (MCI) stage of Alzheimer disease, with supportive biomarkers and no edema risk.

Niels Lund, expert investigator, reveals how early type 2 diabetes care slashes greenhouse gas emissions, boosts life years, and curbs costly complications.

Registry data show COVID-era care disruptions cut 1-year cancer survival, adding 17,390 excess deaths—the biggest losses in late-stage and older patients.

Incretin-based therapies were associated with a lower risk of dementia compared with sulfonylureas in older adults with type 2 diabetes, highlighting potential cognitive benefits relevant to long-term diabetes management.

WADA tracks GLP-1s like Ozempic, Wegovy, and Zepbound at the Olympics as pharmacists weigh muscle-loss risks and sports pharmacy guidance.

Study links GLP-1 receptor agonists plus progestin to lower endometrial cancer risk, hinting at new prevention and treatment paths with fewer hysterectomies.

Both formulations were also well-tolerated and withdrawal was rare.

Patients need evidence that reflects real benefit.

Explore emerging evidence on aspirin’s potential role in reducing cancer risk and improving survival.

The label change removes boxed warnings of cardiovascular disease, breast cancer, and probable dementia from certain hormone replacement therapy products.

Innovent’s trispecific antibody IBI3003 has received FDA fast track designation for R/R MM, supported by early clinical data showing strong efficacy and manageable safety in heavily pretreated and high-risk patients.

NCCN-backed MammaPrint stratifies HR+ breast cancer, pinpointing who needs anthracyclines and how pharmacists help personalize oncology care.